3017050
print

Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel

RAPID AML
Example Reports
Negative
Positive

Icon

Additional Technical Information

Ordering Recommendation

Use upon initial diagnosis or overt relapse of acute myeloid leukemia (AML) to rapidly assess for clinically actionable mutations, including substitutions and smaller insertions and deletions, in select regions of targeted genes that may have prognostic and/or therapeutic significance in AML. For subsequent or more comprehensive analyses, refer to Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing (3016621). This test is NOT intended to detect minimal residual disease (MRD).

New York DOH Approval Status

This test is not New York state approved.

Specimen Required

Patient Preparation
Collect

Lavender (whole blood or bone marrow collected in EDTA), green (peripheral blood or bone marrow collected in sodium heparin)

Specimen Preparation

Whole Blood or Bone Marrow: Transport 2 mL (Min: 1.0 mL)

Storage/Transport Temperature

Whole Blood or Bone Marrow: Refrigerated.

Unacceptable Conditions

Serum, plasma, grossly hemolyzed specimens, buccal brush or swab, FFPE tissue, or frozen samples.

Remarks
Stability

Whole blood: Ambient: 1 week, Refrigerated: 2 weeks, Frozen: Unacceptable
Bone marrow: Ambient: 72 hours, Refrigerated: 1 week, Frozen: Unacceptable

Methodology

Massively Parallel Sequencing

Performed

Varies

Reported

3-7 days

Reference Interval

Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note

The following regions are targeted to detect clinically relevant hotspot mutations, unless otherwise indicated: CEBPA* (NM_004364) exon 1; FLT3 (NM_004119) exons 14, 15, 16, 20; IDH1 (NM_005896) exon 4; IDH2 (NM_002168) exon 4; KIT (NM_000222) exons 8, 9, 10, 11, 17; KRAS (NM_004985) exons 2, 3, 4; NPM1 (NM_002520) exon 11; NRAS (NM_002524) exons 2, 3, 4; TP53*(NM_000546) all coding exons

*CEBPA and TP53 are fully covered; any clinically relevant or potentially relevant variants will be reported. More information about the targeted regions of this test is included in the Additional Technical Information.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
03/18/2024
X
N/A

CPT Codes

81450

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
3017051 Rapid AML Interp 101397-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Acute myeloid leukemia (AML)
  • AML therapeutic targets
  • AML with recurrent/defining genetic abnormalities
  • AML, not otherwise specified
  • de novo AML
  • Fast turn-around therapeutic AML panel
  • High-grade myeloid neoplasm
  • Recurrent AML
  • Relapsed AML
  • Secondary AML
  • Therapy-related AML
  • Therapy-related myeloid neoplasm
Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel